Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

152.59 +2.28 (+1.51%)
Streaming Delayed Price Updated: 1:07 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Issues 2022 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)  
Via Benzinga
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Via Benzinga
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart
Via Benzinga
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Via Benzinga
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Alnylam Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward'
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
Via Benzinga
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Five Best And Worst Performing Healthcare Stocks In December 2022
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
Via Benzinga
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.